Fiji Airways introduces the ‘A333 Antimicrobial Shield’ to treat its facilities in Fiji and its operating and standby aircraft.
Fiji Airways is the national airline of the Pacific nation of Fiji, and a connect member of the global oneworld alliance. It plays a critical role in supporting the nation’s vital tourism industry, and in connecting people and freight across a network of 11 domestic and 23 international destinations.
Since the outbreak of the COVID-19 pandemic, Fiji Airways, like every airline, has dramatically reduced scheduled operations and contracted its network in line with restricted access to international destinations.
But it has continued to operate limited domestic flights for passengers and freight, a growing number of special repatriation flights to and from Fiji, and cargo charters to ensure the continued flow of Fiji’s fresh produce to key export markets and the supply of essential imports.
To help protect its passengers, employees, suppliers, and the communities of Fiji, the national airline has intensified its hygiene protocols by introducing the ‘A333 Antimicrobial Shield’ to treat its facilities in Fiji, and its operating and standby aircraft, a mix of ATR 42 and 72 turboprops, Boeing 737-800s, widebody Airbus A330s and A350s, and more as the airline gradually rebuilds services.
Produced by Australian company Hygiene Labs, and distributed by sister company 1, 145 Aviation Services, the A333 treatment is delivered through both fogging and direct surface applications.
It has been independently verified to kill surface-borne COVID-19 for up to 28 days. It has also been listed by Australia’s Therapeutic Goods Administration, the national regulator of such products.
Hygiene Labs is proud to support Fiji Airways.